bioAffinity Technologies partners with Pictor to develop asthma, COPD diagnostics

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc.

BIAF

0.00
  • bioAffinity Technologies partnered with Pictor to develop and commercialize next-generation diagnostic tests for asthma and COPD.
  • Collaboration combines bioAffinity’s sputum-based flow cytometry with Pictor’s targeted proteomics to profile immune cells and cytokines.
  • Program targets a high-throughput lab test to guide precision treatment decisions, including use of FDA-approved biologics.
  • Initial launches expected as CLIA laboratory developed tests; bioAffinity to own test-related IP, Pictor to retain platform IP.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722558457) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.